ES2135342B1 - Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. - Google Patents

Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.

Info

Publication number
ES2135342B1
ES2135342B1 ES009702224A ES9702224A ES2135342B1 ES 2135342 B1 ES2135342 B1 ES 2135342B1 ES 009702224 A ES009702224 A ES 009702224A ES 9702224 A ES9702224 A ES 9702224A ES 2135342 B1 ES2135342 B1 ES 2135342B1
Authority
ES
Spain
Prior art keywords
breast cancer
salt
preparation
raloxifeno
salvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009702224A
Other languages
English (en)
Other versions
ES2135342A1 (es
Inventor
Frederic Jay Cohen
Joan Ellen Glusman
Ronald Keith Knickerbocker
Nikolaus Thomas Nickelsen
Teri Janine Scott
Robert Stephen Eckert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2135342(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES2135342A1 publication Critical patent/ES2135342A1/es
Application granted granted Critical
Publication of ES2135342B1 publication Critical patent/ES2135342B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Uso del raloxifeno o una sal o solvato del mismo en la preparación de un medicamento para prevenir el cáncer de mama. Un procedimiento para prevenir el cáncer de mama, que comprende administrar durante un período suficiente a un ser humano que lo necesite una cantidad eficaz de un compuesto que tiene la fórmula I, y las sales y solvatos farmacéuticamente aceptables del mismo.
ES009702224A 1996-10-30 1997-10-28 Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. Expired - Fee Related ES2135342B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10

Publications (2)

Publication Number Publication Date
ES2135342A1 ES2135342A1 (es) 1999-10-16
ES2135342B1 true ES2135342B1 (es) 2000-05-16

Family

ID=27268608

Family Applications (4)

Application Number Title Priority Date Filing Date
ES009702224A Expired - Fee Related ES2135342B1 (es) 1996-10-30 1997-10-28 Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES09702225A Withdrawn ES2135343A1 (es) 1996-10-30 1997-10-28 Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.
ES97308588T Expired - Lifetime ES2197312T3 (es) 1996-10-30 1997-10-29 Mejoras en o en relacion con la profilaxis del cancer de mama por administracion de raloxifeno.
ES03102726T Expired - Lifetime ES2271476T3 (es) 1996-10-30 1997-10-29 Procedimientos de prevencion de cancer de mama por administracion de raloxifeno.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES09702225A Withdrawn ES2135343A1 (es) 1996-10-30 1997-10-28 Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.
ES97308588T Expired - Lifetime ES2197312T3 (es) 1996-10-30 1997-10-29 Mejoras en o en relacion con la profilaxis del cancer de mama por administracion de raloxifeno.
ES03102726T Expired - Lifetime ES2271476T3 (es) 1996-10-30 1997-10-29 Procedimientos de prevencion de cancer de mama por administracion de raloxifeno.

Country Status (44)

Country Link
US (2) US6303634B1 (es)
EP (3) EP1369115B1 (es)
JP (2) JPH10147529A (es)
CN (2) CN1182590A (es)
AP (1) AP971A (es)
AR (2) AR013864A1 (es)
AT (2) ATE239475T1 (es)
AU (3) AU5005697A (es)
BE (2) BE1011382A5 (es)
BG (1) BG63841B1 (es)
BR (1) BR9712703A (es)
CA (2) CA2219377A1 (es)
CH (2) CH693820A5 (es)
CZ (2) CZ300261B6 (es)
DE (2) DE69736644T2 (es)
DK (2) DK0839532T3 (es)
EA (2) EA002054B1 (es)
EE (1) EE03663B1 (es)
ES (4) ES2135342B1 (es)
FR (2) FR2756490B1 (es)
GB (3) GB2318733A (es)
GE (1) GEP20032910B (es)
GR (2) GR970100409A (es)
HK (1) HK1010495A1 (es)
HU (2) HUP9701778A3 (es)
IE (2) IE970772A1 (es)
IL (2) IL122026A0 (es)
IS (1) IS5035A (es)
IT (2) IT1298470B1 (es)
LU (2) LU90157B1 (es)
LV (1) LV12353B (es)
MY (1) MY121623A (es)
NL (2) NL1007386C2 (es)
NO (2) NO322468B1 (es)
NZ (1) NZ329042A (es)
PT (2) PT1369115E (es)
RO (1) RO120813B1 (es)
SG (2) SG72765A1 (es)
SI (3) SI20107A (es)
SK (1) SK287047B6 (es)
TR (1) TR199900951T2 (es)
UA (1) UA46762C2 (es)
WO (2) WO1998018449A1 (es)
YU (1) YU42397A (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
JP2004531559A (ja) 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
WO2002094788A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
HUT71237A (en) * 1993-10-15 1995-11-28 Lilly Co Eli Pharmaceutical compositions for treating resistant neoplasms containing 2-phenyl-3-aroil-benzotiophene derivatives and process for their preparation
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
ZA951497B (en) * 1994-03-02 1996-08-23 Lilly Co Eli Orally administerable pharmaceutical formulations
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
IL140742A (en) * 1996-03-26 2012-02-29 Lilly Co Eli Reloxifen and pharmaceuticals containing it

Also Published As

Publication number Publication date
AP971A (en) 2001-05-30
ES2135343A1 (es) 1999-10-16
GB9911557D0 (en) 1999-07-21
IL122026A0 (en) 1998-03-10
AU4364797A (en) 1998-05-07
EA200100716A1 (ru) 2002-06-27
ES2271476T3 (es) 2007-04-16
LV12353A (lv) 1999-10-20
GR1003189B (el) 1999-09-01
ES2135342A1 (es) 1999-10-16
PT839532E (pt) 2003-09-30
LU90157B1 (fr) 1998-06-02
DK0839532T3 (da) 2003-08-25
MX9708341A (es) 1998-08-30
BR9712703A (pt) 1999-10-26
AU5005197A (en) 1998-05-22
AP9901494A0 (en) 1999-03-31
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
CA2219070A1 (en) 1998-04-30
BG103369A (en) 2000-05-31
FR2755014B1 (fr) 1999-02-05
CH691847A5 (fr) 2001-11-15
LV12353B (en) 2000-02-20
EP0839533A1 (en) 1998-05-06
SK55999A3 (en) 2000-06-12
GEP20032910B (en) 2003-03-25
EP1369115B1 (en) 2006-09-06
ATE338551T1 (de) 2006-09-15
SK287047B6 (sk) 2009-10-07
IE970773A1 (en) 2000-02-09
HUP9701777A3 (en) 1999-07-28
IS5035A (is) 1999-04-27
AU4364897A (en) 1998-05-07
IL122025A0 (en) 1998-03-10
GR970100409A (el) 1998-06-30
CA2219377A1 (en) 1998-04-30
CN1182591A (zh) 1998-05-27
EA002054B1 (ru) 2001-12-24
NO974973D0 (no) 1997-10-28
ES2197312T3 (es) 2004-01-01
NO322468B1 (no) 2006-10-09
EP0839532B1 (en) 2003-05-07
GR970100408A (el) 1998-06-30
SG83672A1 (en) 2001-10-16
DE69721692D1 (de) 2003-06-12
SI20107A (sl) 2000-06-30
GB9722796D0 (en) 1997-12-24
HUP9701778A3 (en) 1999-06-28
CZ341297A3 (cs) 1998-05-13
NO974972L (no) 1998-05-04
CZ300261B6 (cs) 2009-04-01
MY121623A (en) 2006-02-28
NO974972D0 (no) 1997-10-28
FR2756490A1 (fr) 1998-06-05
EE9900162A (et) 1999-12-15
GB2318734A (en) 1998-05-06
EE03663B1 (et) 2002-04-15
HUP9701777A2 (hu) 1999-06-28
AR013864A1 (es) 2001-01-31
GB2318734B (en) 1999-12-01
PT1369115E (pt) 2006-12-29
DE69736644T2 (de) 2007-10-25
BE1011382A5 (fr) 1999-08-03
WO1998018325A1 (en) 1998-05-07
ITMI972433A1 (it) 1999-04-29
EP0839532A1 (en) 1998-05-06
YU42397A (sh) 2000-10-30
AU5005697A (en) 1998-05-22
UA46762C2 (uk) 2002-06-17
FR2755014A1 (fr) 1998-04-30
SI0839532T1 (en) 2003-10-31
GB9722801D0 (en) 1997-12-24
ITMI972434A1 (it) 1999-04-29
IL122025A (en) 2003-01-12
CZ341197A3 (cs) 1998-05-13
NL1007387C2 (nl) 1998-05-14
AU731388B2 (en) 2001-03-29
EA006083B1 (ru) 2005-08-25
US6303634B1 (en) 2001-10-16
FR2756490B1 (fr) 2003-06-20
DE69721692T2 (de) 2004-03-25
SI1369115T1 (sl) 2006-12-31
IE970772A1 (en) 2000-02-09
CH693820A5 (fr) 2004-02-27
CA2219070C (en) 2007-12-18
ATE239475T1 (de) 2003-05-15
TR199900951T2 (xx) 1999-07-21
BG63841B1 (bg) 2003-03-31
US20020019418A1 (en) 2002-02-14
CN1182590A (zh) 1998-05-27
GB2318733A (en) 1998-05-06
EP1369115A1 (en) 2003-12-10
JPH10147529A (ja) 1998-06-02
NZ329042A (en) 1999-08-30
JPH10147530A (ja) 1998-06-02
RO120813B1 (ro) 2006-08-30
AR010538A1 (es) 2000-06-28
BE1011381A5 (fr) 1999-08-03
IT1298470B1 (it) 2000-01-10
DK1369115T3 (da) 2007-01-02
DE69736644D1 (de) 2006-10-19
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
HUP9701778A2 (hu) 1999-01-28
HK1010495A1 (en) 1999-06-25
SG72765A1 (en) 2000-05-23
WO1998018449A1 (en) 1998-05-07
EA199900431A1 (ru) 1999-10-28
NL1007386C2 (nl) 1998-05-14

Similar Documents

Publication Publication Date Title
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
MX9304432A (es) Compuestos y formulaciones farmaceuticas para el tratamiento o prevencion de la osteoporosis y la perdida de los huesos.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
DE60143911D1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
ES2020171T3 (es) Eteres de 1-bencil-3-hidroximetilindazol con 2-hidroxiacidos alifaticos.
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
ES2059058T3 (es) Combinacion sinergica para uso oftalmico.
ATE169922T1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
MX9203735A (es) Una forma de dosis mejorada para suministrar una droga o un agente terapeutico a un ambiente de uso.
SE9000948D0 (sv) New use
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
SE7708622L (sv) 2-bensyl-perhydroazepiner, sett for framstellning derav och lekemedel, innehallande dem
MX9302832A (es) Nuevo medicamento para el tratamiento de la arritmia.
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991016

Kind code of ref document: A1

Effective date: 19991016

FD1A Patent lapsed

Effective date: 20100616